Stoke Therapeutics enrolls first patient in natural history study of ADOA
August 25, 2022
Stoke Therapeutics enrolls its first patient in a prospective natural history study of people living with autosomal dominant optic atrophy that seeks to understand what causes the condition. Julie Falardeau, M.D., says, the study will generate "data that will provide new insights into how the disease affects patients, which will be important as we study potential new treatments."